VRSK vs INSM Comparison

Verisk Analytics is a leading provider of data analytics and proprietary solutions supporting clients within the insurance ecosystem. Verisk operates under a single segment with two separate business units, underwriting and claims. Within underwriting, the company operates as both a statistical agent and advisory organization collecting and aggregating industrywide claims and policy data and providing insurers with pre-approved forms, rules, and loss costs. Aside from their regulatory and compliance offerings, Verisk provides specialized solutions utilized to power P&C underwriting and catastrophe risk assessment used in reinsurance and insurance-linked securities. Verisk's smaller claims business is critical in preventing fraud and estimating property insurance claims.

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.